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Abstract
Drug development is an expensive process that is marked by a high-failure rate. For this reason 
early stage bioequivalence and pharmacokinetic studies are essential in determining the fate of 
new drug products. In this study, we sought to systematically assess the current trends of ongoing 
and recently completed bioequivalence and bioavailability trials that have been registered within a 
national clinical trials registry. All bioequivalence and bioavailability studies registered in the 
United States ClinicalTrials.gov registry from late-2007 through 2011 were identified. Over this 
period, more than 2300 interventional bioequivalence and bioavailability trials were registered. As 
of 2013, the vast majority of studies (86%) have been completed, 10% are actively recruiting 
participants, and the remainder are engaged in data analysis (4%). When compared to completed 
trials, ongoing trials are in later phases of clinical development, recruiting larger numbers of 
participants, and more likely to recruit women and children (P<0.001 for all). These data suggest 
that the quality of bioequivalence and bioavailability studies has improved rapidly, even over the 
last five years. However, further work is needed to sustain – and accelerate – these improvements 
in the design of bioequivalence and bioavailability studies to ensure that safe and efficacious 
medicines swiftly reach healthcare providers and their patients.
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Introduction
Many drug patents have recently expired or are scheduled to expire in the near future [1]. In 
response, many drug manufacturers have expanded their generic drug portfolio, which 
requires them to conduct clinical trials that demonstrate that their generic equivalents 
perform similarly to the innovator drug product [2]. Regulations introduced by the United 
States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) 
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over the last thirty-five years have strengthened measures to ensure the bioequivalency of 
drug products, which may be simultaneously manufactured by multiple drug makers [3-5]. 
Bioequivalence and bioavailability testing standards have also emerged following 
recognition that bioinequivalence and variations in the bioavailability of drug products can 
result in therapeutic failure and/or toxicity [6-8].
In the United States, the successful approval of new and abbreviated new drug applications 
requires regulatory approval by the FDA [9]. Recent studies have suggested that this process 
takes nearly a decade to complete the required series of pre-clinical studies and clinical trials 
[10]. Drug development is an expensive process that is marked by a high-failure rate [11]. 
For these reasons, early stage bioequivalence and pharmacokinetic studies are essential in 
determining the fate of new drug products.
In this study, we sought to systematically assess the current trends of ongoing and recently 
completed bioequivalence and bioavailability trials that have been registered within a 
national clinical trials registry. This study provides insight regarding the characteristics of 
current bioequivalence and bioavailability trials and may also provide assistance in 
prioritizing future areas of research.]
Methods
Selection of bioequivalence and bioavailability trials
We identified bioequivalence and bioavailability trials registered in ClinicalTrials.gov using 
the key words “bioequivalence” and “bioavailability”. Briefly, ClinicalTrials.gov is a 
publicly-available registry of clinical research studies that is maintained by the U.S. National 
Institutes of Health. As of mid-2013 there were nearly 150,000 studies registered in 
ClinicalTrials.gov, with study sites in 185 countries (http://www.clinicaltrials.gov).
Our search was restricted to identify studies registered between 01 October 2007 and 31 
December 2012 to coincide with the enactment of a federal law in 2007 that mandated the 
registration of all phase 2-4 interventional trials involving drugs, biological agents, and 
medical devices [12]. We excluded all observational trials (n=34) as well as trials that were 
“suspended” (n=7), “terminated” (n=33), or “withdrawn” (n=26). The remaining trial 
registry entries were systematically examined and the following data elements were 
extracted: a unique trial identifier, study title, recruitment status, phase (0-4), study design, 
blinding status, interventional assignment to trial arms, primary endpoint classification, 
primary purpose of the trial, age group and gender eligibility criteria, and anticipated 
enrollment size.
Statistical analyses
Descriptive statistics were used to characterize the bioequivalence and bioavailability trials 
identified in the ClinicalTrials.gov registry. Comparisons between ongoing trials and those 
that have been completed were performed using the χ2-test or Fisher’s exact test. 
Continuous variables were compared with the non-parametric Kruskal-Wallis test. All 
statistical analyses were undertaken in Stata 11.2 (StataCorp LP, College Station, TX, USA).
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From October 2007 through December 2012 there were 2,388 interventional bioequivalence 
and bioavailability trials registered in ClinicalTrials.gov. Of these, 227 (10%) trials are 
actively recruiting participants, 15 (1%) are recruiting by invitation only, 87 (4%) are 
engaged in data analysis, and 2,059 (86%) have been completed. The 15 most commonly 
investigated disease states / conditions are featured in Figure 1.
A comparison of ongoing and completed clinical trial characteristics is presented in Table 1. 
Ongoing bioequivalence and bioavailability trials are more likely to be in later phase clinical 
trials, as reflected by a decrease in the proportion of phase 0, 1, and 1/2 trials from 75% 
among completed studies to 36% of ongoing studies (P<0.001). Ongoing trials are also more 
likely to be double-blinded (27% vs. 12%; P<0.001) and have larger sample sizes (P<0.001). 
Similarly, ongoing trials are more likely to feature parallel group assignment and less likely 
to be crossover trials (P<0.001 for both). There has also been an increase in the proportion of 
trials that primarily involved research on treatments from 42% to 55% (P<0.001). The 
proportion of trials that exclusively recruited male participants declined from 20% to 9% 
(P<0.001) and the number of trials that enrolled children increased from 3% to 17% 
(P<0.001).
Geographic distribution
More than half of the bioequivalence and bioavailability trials registered in 
ClinicalTrials.gov were conducted internationally (58%). Among ongoing trials, 48% are 
being conducted at sites located outside of North America. The global distribution of 
ongoing bioequivalence and bioavailability trials is shown in Figure 2. The majority of 
ongoing trials are recruiting participants in North America (52%) and Europe (26%); 
however, East Asia (7%), the Middle East (4%), and South America (4%) are also involved 
in several ongoing bioequivalence and bioavailability trials.
Discussion
This study reveals that bioequivalence and bioavailability trials are part of a global clinical 
research enterprise. When compared to completed trials, ongoing trials are in later phases of 
clinical development, recruiting larger numbers of participants, and more likely to recruit 
women and children. These data suggest that bioequivalence and bioavailability studies are 
undergoing a transformation as drug makers seek to characterize the safety and efficacy of 
drug products in more rigorous trials that closely resemble their anticipated patient 
population.
As the costs of healthcare and drug development have risen, there is a mounting incentive 
for improving our understanding of existing treatments while also enabling breakthrough 
discoveries [13]. Recently, the United Kingdom has attempted to strategically align their 
clinical research funding with their public health priorities [14]. Although similar measures 
have not been enacted in the United States, it behooves policy makers to consider the vital 
role that bioequivalence and bioavailability studies play in bringing new and generic drug 
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products to the public. As noted here, the quality of bioequivalence and bioavailability 
studies has improved rapidly, even over the last five years, and the horizon is bright. 
However, as the national debate on healthcare reform and research priorities unfolds we may 
need to re-evaluate our approach to bioequivalence and bioavailability trials to ensure that 
safe and efficacious medicines swiftly reach healthcare providers and their patients.
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Distribution of the 15 most commonly researched disease states / conditions among 
bioequivalence and bioavailability studies registered in ClinicalTrials.gov.
Stockmann et al. Page 6














Global distribution of ongoing bioequivalence and bioavailability trials registered in 
ClinicalTrials.gov in 2013. The size of the blue circles denotes the number of ongoing 
clinical trials within each geographic region.
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Table 1
Interventional bioequivalence and bioavailability clinical trial characteristics among ongoing and completed 
trials.
Characteristic Category
Bioequivalence & Bioavailability Trials
Ongoing (n = 227) Completed (n = 2,161)
Study phase, n (%) Phase 0, 1, 1/2 82 (36) 1,625 (75)
Phase 2, 2/3 31 (14) 51 (2)
Phase 3, 4 57 (25) 120 (6)
Unknown / missing 57 (25) 365 (17)
Allocation status, n (%) Randomized 172 (76) 1,955 (90)
Non-randomized 21 (9) 94 (4)
Unknown / missing 34 (15) 112 (5)
Blinding, n (%) Open 141 (62) 1,751 (81)
Single blind 24 (11) 114 (5)
Double blind 62 (27) 252 (12)
Unknown / missing 0 (0) 44 (2)
Interventional group, n (%) Single group 55 (24) 151 (7)
Parallel 98 (43) 249 (12)
Cross-over 69 (30) 1,707 (79)
Factorial 5 (2) 8 (<1)
Unknown / missing 0 (0) 46 (2)
Endpoint classification, n (%) Bioavailability 47 (21) 418 (19)
Bioequivalence 108 (48) 1,270 (59)
Efficacy 14 (6) 26 (1)
Pharmacokinetics and/or pharmacodynamics 16 (7) 239 (11)
Safety 14 (6) 64 (3)
Safety / efficacy 18 (8) 20 (1)
Unknown / missing 10 (4) 124 (6)
Primary purpose, n (%) Treatment 125 (55) 911 (42)
Basic science 28 (12) 317 (15)
Prevention 20 (9) 61 (3)
Diagnostic 17 (7) 20 (1)
Health services research 3 (1) 16 (1)
Supportive care 6 (3) 7 (<1)
Screening 0 (0) 7 (<1)
Missing 28 (12) 822 (38)
Sex, n (%) Female only 21 (9) 113 (5)
Male only 20 (9) 424 (20)
Both 186 (82) 1,616 (75)
Unknown / missing 0 (0) 8 (<1)
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Characteristic Category
Bioequivalence & Bioavailability Trials
Ongoing (n = 227) Completed (n = 2,161)
Age groups, n (%) Children only 17 (7) 30 (1)
Children and adults 23 (10) 48 (2)
Adults only 187 (82) 2,083 (96)
Expected sample size, median (IQR) 50 (24 – 104) 32 (24 – 48)
J Bioequivalence Bioavailab. Author manuscript; available in PMC 2014 October 17.
